Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Turcot syndrome 2Medulloblastoma 2Triple Negative Breast Neoplasms 1Solid Tumor 1Rhabdoid Tumor 1Recurrence 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Pinealoma 1Peutz-Jeghers Syndrome 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Mouth Neoplasms 1Locally Advanced Rectal Cancer 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Ependymoma 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1Adenomatous Polyposis Coli 1

Interventions

Capecitabine 7Oxaliplatin 6toripalimab 2camrelizumab 2Immune Checkpoint Inhibitors 2Fluorouracil 2spartalizumab 1irinotecan sucrosofate 1Radiotherapy, Intensity-Modulated 1Leucovorin 1Irinotecan 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Locally Advanced Rectal Cancer × Celecoxib × Clear all
NCT07150949 2025-09-02

Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)

Fudan University

Phase 2 Recruiting
138 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡